Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug By: Benzinga via Benzinga April 14, 2015 at 15:38 PM EDT Arrowhead Research Corp (NASDAQ: ARWR)'s hepatitis B medicine may prove a cure for the disease, but early data are unimpressive, an ... Read More >> Related Stocks: Gilead Sciences